ArticleCell communication and signaling : CCS2026
Investigating the impact and mechanism of Licochalcone B derivative CTG12 on NLRP3 inflammasome.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAberrant activation of NLRP3 inflammasome has been associated with a variety of human inflammatory diseases, but no small molecule inhibitors of NLRP3 were applied in clinical practice. Our research group has previously shown that licochalcone B is an effective NLRP3 inflammasome inhibitor, however, its IC50 value is relatively high compared to compounds such as MCC950. Modifying bioactive natural products to find NLRP3 inflammasome inhibitors with stronger potency and higher specificity is a direction worthy of investigation. PURPOSE: Our research aims to evaluate the impact of various licochalcone B derivatives on NLRP3 inflammasome, to screen for derivatives with better potency and elucidate the underlying mechanisms.
methodsWe investigated the effects of licochalcone B and its derivatives on NLRP3 inflammasome by assessing the production of active caspase-1 and interleukin 1β (IL-1β). To elucidate the mechanism of CTG12, we employed co-immunoprecipitation. Furthermore, we evaluated CTG12 in LPS-induced acute systemic inflammation mouse models.
resultsThe findings demonstrated that licochalcone B and its derivatives effectively inhibit NLRP3 inflammasome. CTG12 exhibits the most potent inhibitory activity, showing approximately tenfold increased effects compared to licochalcone B. Mechanistic investigations reveal that while CTG12 does not affect potassium (K⁺) efflux, calcium (Ca2⁺) influx, or mitochondrial reactive oxygen species (mtROS) production, it suppressed NLRP3 assembly by interfering with the ASC-NLRP3 interaction and the NLRP3-dependent ASC oligomerization process. In vivo, CTG12 provides significant therapeutic benefits in LPS-induced acute systemic inflammation models.
conclusionOur results indicated that structurally modified licochalcone B derivative CTG12 inhibits NLRP3 assembly by interfering with the ASC-NLRP3 interaction, thereby inhibiting the NLRP3-dependent ASC oligomerization process in NLRP3 inflammasome activation. These studies would show that CTG12 is a valuable small molecule inhibitor that holds promise as a high-value drug candidate for the treatment of NLRP3-mediated inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.